AAAAAA
Results: 1-25/37
Authors:
Amant, F
Dorfling, CM
Dreyer, L
Vergote, I
Lindeque, BG
Van Rensburg, EJ
Citation: F. Amant et al., Microsatellite instability in uterine sarcomas, INT J GYN C, 11(3), 2001, pp. 218-223
Authors:
Amant, F
Debiec-Rychter, M
Schoenmakers, EFPM
Hagemeijer-Hausman, A
Vergote, I
Citation: F. Amant et al., Cumulative dosage effect of a RAD51L1/HMGA2 fusion and RAD51L1 loss in a case of Pseudo-Meigs' syndrome, GENE CHROM, 32(4), 2001, pp. 324-329
Authors:
Duffaud, F
van der Burg, MEL
Namer, M
Vergote, I
Willemse, PHB
Huinink, WT
Guastalla, JP
Nooij, MA
Kerbrat, P
Piccart, M
Tumolo, S
Favalli, G
van der Vange, N
Lacave, AJ
Wils, J
Splinter, TAW
Einhorn, N
Roozendaal, KJ
Rosso, R
Vermorken, JB
Citation: F. Duffaud et al., D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTCgynaecological cancer co-operative group study, ANTI-CANC D, 12(2), 2001, pp. 159-162
Authors:
Vergote, I
Citation: I. Vergote, Jan Bonte - In memoriam, EUR J GYN O, 22(3), 2001, pp. 174-174
Authors:
Wagenaar, HC
Pecorelli, S
Vergote, I
Curran, D
Wagener, DJT
Kobierska, A
Bolis, G
ten Bokkel-Huinink, W
Lacave, AJ
Madronal, C
Forni, M
de Oliveira, CF
Mangioni, C
Nooij, MA
Goupil, A
Kerbrat, P
Marth, C
Tumolo, S
Herben, MG
Zanaboni, F
Vermorken, JB
Citation: Hc. Wagenaar et al., Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma - An EORTC Gynecological Cancer Group Study, EUR J GYN O, 22(3), 2001, pp. 187-193
Authors:
Amant, F
Dreyer, L
Makin, J
Vergote, I
Lindeque, BG
Citation: F. Amant et al., Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations, EUR J GYN O, 22(3), 2001, pp. 194-200
Authors:
Amant, F
Moerman, P
Davel, GH
De Vos, R
Vergote, I
Lindeque, BG
de Jonge, E
Citation: F. Amant et al., Uterine carcinosarcoma with melanocytic differentiation, INT J GYN P, 20(2), 2001, pp. 186-190
Authors:
Vergote, I
Timmerman, D
Fyles, A
Trope, CG
De Brabanter, J
Citation: I. Vergote et al., Cyst rupture during surgery - Authors' reply, LANCET, 358(9275), 2001, pp. 73-73
Authors:
Vergote, I
De Brabanter, J
Fyles, A
Bertelsen, K
Einhorn, N
Sevelda, P
Gore, ME
Kaern, J
Verrelst, H
Sjovall, K
Timmerman, D
Vandewalle, J
Van Gramberen, M
Trope, CG
Citation: I. Vergote et al., Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma, LANCET, 357(9251), 2001, pp. 176-182
Authors:
Amant, F
Gabriel, C
Timmerman, D
Vergote, I
Citation: F. Amant et al., Pseudo-Meigs' syndrome caused by a hydropic degenerating uterine leiomyomawith elevated CA 125, GYNECOL ONC, 83(1), 2001, pp. 153-157
Authors:
Timmerman, D
Verrelst, H
Collins, WP
Bourne, TH
Vergote, I
Citation: D. Timmerman et al., Possible influence of granulocyte colony-stimulating factor and recombinant human erythropoietin on human chorionic gonadotropin secretion during chemotherapy for choriocarcinoma, GYNECOL ONC, 83(1), 2001, pp. 166-167
Authors:
Wagenaar, HC
Colombo, N
Vergote, I
Hoctin-Boes, G
Zanetta, G
Pecorelli, S
Lacave, AJ
van Hoesel, Q
Cervantes, A
Bolis, G
Namer, M
Lhomme, C
Guastalla, JP
Nooij, MA
Poveda, A
di Palumbo, VS
Vermorken, JB
Citation: Hc. Wagenaar et al., Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: An EORTC Gynaecological Cancer Cooperative Group study, GYNECOL ONC, 81(3), 2001, pp. 348-354
Authors:
Vergote, I
de Wever, I
Tjalma, W
Van Gramberen, M
Decloedt, J
Van Dam, P
Citation: I. Vergote et al., Interval debulking surgery: An alternative for primary surgical debulking?, SEM SURG ON, 19(1), 2000, pp. 49-53
Authors:
Piccart, MJ
Bertelsen, K
James, K
Cassidy, J
Mangioni, C
Simonsen, E
Stuart, G
Kaye, S
Vergote, I
Blom, R
Grimshaw, R
Atkinson, RJ
Swenerton, KD
Trope, C
Nardi, M
Kaern, J
Tumolo, S
Timmers, P
Roy, JA
Lhoas, F
Lindvall, B
Bacon, M
Birt, A
Andersen, JE
Zee, B
Paul, J
Baron, B
Pecorelli, S
Citation: Mj. Piccart et al., Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results, J NAT CANC, 92(9), 2000, pp. 699-708
Authors:
Vergote, I
Rustin, GJS
Eisenhauer, EA
Kristensen, GB
Pujade-Lauraine, E
Parmar, MKB
Friedlander, M
Jakobsen, A
Vermorken, JB
Citation: I. Vergote et al., Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer], J NAT CANC, 92(18), 2000, pp. 1534-1535
Authors:
Thompson-Hehir, J
Davies, MPA
Green, JA
Halliwell, N
Joyce, KA
Salisbury, J
Sibson, DR
Vergote, I
Walker, C
Citation: J. Thompson-hehir et al., Novel polymerase chain reaction approach for full-coding p53 mutation detection in microdissected archival tumors, DIAGN MOL P, 9(2), 2000, pp. 110-119
Authors:
Timmerman, D
Valentin, L
Bourne, TH
Collins, WP
Verrelst, H
Vergote, I
Citation: D. Timmerman et al., Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group, ULTRASOUN O, 16(5), 2000, pp. 500-505
Authors:
Vergote, I
Neven, P
van Dam, P
Serreyn, R
De Prins, F
De Sutter, P
Albertyn, G
Citation: I. Vergote et al., The oestrogen receptor and its selective modulators in gynaecological and breast cancer, EUR J CANC, 36, 2000, pp. S1-S9
Authors:
Timmerman, D
Deprest, J
Verbesselt, R
Moerman, P
De Brabanter, J
Vergote, I
Citation: D. Timmerman et al., Absence of correlation between risk factors for endometrial cancer and thepresence of tamoxifen-associated endometrial polyps in postmenopausal patients with breast cancer, EUR J CANC, 36, 2000, pp. S40-S42
Authors:
Vergote, I
Bonneterre, J
Thurlimann, B
Robertson, J
Krzakowski, M
Mauriac, L
Koralewski, L
Webster, A
Steinberg, M
von Euler, M
Citation: I. Vergote et al., Randomised study of anastrozole versus tamoxifen as first-line therapy foradvanced breast cancer in postmenopausal women, EUR J CANC, 36, 2000, pp. S84-S85
Authors:
Blamey, R
Blichert-Toft, M
Cataliotti, L
Costa, A
Greco, M
Holland, R
Kaufmann, M
Perry, N
Ponti, A
Redmond, K
Sainsbury, R
van de Velde, C
Christiaens, M
Jassem, J
Julien, JP
Paridaens, R
Rutgers, E
van Limbergen, EF
Van den Bogaert, W
Vergote, I
Wildiers, J
Citation: R. Blamey et al., The requirements of a specialist breast unit, EUR J CANC, 36(18), 2000, pp. 2288-2293
Authors:
Trope, C
Kaern, J
Hogberg, T
Abeler, V
Hagen, B
Kristensen, G
Onsrud, M
Pettersen, E
Rosenberg, P
Sandvei, R
Sundfor, K
Vergote, I
Citation: C. Trope et al., Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument, ANN ONCOL, 11(3), 2000, pp. 281-288
Authors:
Piccart, MJ
Green, JA
Lacave, AJ
Reed, N
Vergote, I
Benedetti-Panici, P
Bonetti, A
Kristeller-Tome, V
Fernandez, CM
Curran, D
Van Glabbeke, M
Lacombe, D
Pinel, MC
Pecorelli, S
Citation: Mj. Piccart et al., Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group, J CL ONCOL, 18(6), 2000, pp. 1193-1202
Authors:
Hoskins, P
Eisenhauer, E
Vergote, I
Dubuc-Lissoir, J
Fisher, B
Grimshaw, R
Oza, A
Plante, M
Stuart, G
Vermorken, J
Citation: P. Hoskins et al., Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group Study, J CL ONCOL, 18(24), 2000, pp. 4038-4044
Authors:
Bonneterre, J
Thurlimann, B
Robertson, JFR
Krzakowski, M
Mauriac, L
Koralewski, P
Vergote, I
Webster, A
Steinberg, M
von Euler, M
Citation: J. Bonneterre et al., Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study, J CL ONCOL, 18(22), 2000, pp. 3748-3757